Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis

Juliane Havlicek, Beatrice Dachsel, Peter Slickers, Sönke Andres, Patrick Beckert, Silke Feuerriegel, Stefan Niemann, Matthias Merker*, Ines Labugger

*Corresponding author for this work


Pyrazinamide (PZA)is a key antibiotic for the treatment of drug susceptible tuberculosis. PZA-resistance is mainly mediated by mutations in the pncA gene; however the current gold standard is a phenotypic drug susceptibility test requiring a well-adjusted pH-value for reliable results. Our melting curve assay detects a non-wild type genotype in selected pncA regions in at least 3750 gene copies/mL within 2.5 hours. The prototype assay was further evaluated by analyzing 271 Mycobacterium tuberculosis complex isolates from Swaziland originating from a previously published drug resistance survey and including 118 isolates with pncA mutations. Sensitivity was 83% (95% CI 75–89%)and specificity was 100% (95% CI 98–100%). Under consideration of further improvements with regard to the target range our melting curve assay has the potential as a rapid rule-in test for PZA susceptibility (wild type pncA), however false resistant results (mutant pncA, but PZA susceptible)cannot be ruled out completely.

Original languageEnglish
JournalDiagnostic Microbiology and Infectious Disease
Issue number2
Pages (from-to)147-154
Number of pages8
Publication statusPublished - 06.2019

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)


Dive into the research topics of 'Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this